ULTIMATE
ULTIMATE BIG 16-01 Share This Post An open-label, multicentre, international phase II trial testing durvalumab combined with endocrine therapy in patients with ER+/HER2- breast cancer
TRANSBIG
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group to promote collaboration in translational breast cancer research.
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group (BIG) to promote collaboration in translational breast cancer research. TRANSBIG’s main focus was an international clinical trial known as MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy), which is sponsored by the European Organisation for the Research and Treatment of Cancer (EORTC) (www.eortc.org) and enrolled more than 6693 women in 9 European countries.
TRANSBIG’s overall aim was to individualise treatment by rapidly “translating” the latest discoveries in cancer biology made by laboratory scientists into tools that doctors can use to help make decisions about the way to treat patients.
This is because a refinement in prognosis allows for better prediction of the outcome of treatment and can thereby reduce the proportion of women receiving chemotherapy. This would simultaneously avoid unnecessary exposure to toxicity and harmful long-term side effects. The cost of cancer care would decrease, as would the burden on European health care systems.
TRANSBIG’s goal was achieved through the MINDACT clinical trial, which showed that a 70-gene signature, commercially known as MammaPrint®, when used in addition to common clinical-pathological criteria, could identify patients who could be spared adjuvant chemotherapy.
TRANSBIG ran a major international clinical trial called MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) to test a 70-gene tool (MammaPrint®) to identify which women needed chemotherapy after surgery and which did not. More information can be found here.
39 partners in 21 countries include the European and Latin American leaders in cancer treatment, genomics, microarray technology, proteomics, bioinformatics and biostatistics. Other critical elements in the fight against breast cancer are integrated into the TRANSBIG consortium as well: a patient advocacy network and a federation of cancer societies.
Breast International Group (BIG-aisbl), Brussels | International (Coordinator) |
Institut Jules Bordet / Jules Bordet Instituut, Brussels | Belguim |
The Netherlands Cancer Institute, Amsterdam | Netherlands |
Istituto Europeo di Oncologia – European Institute of Oncology | Italy |
Karolinska Institute & Hospital, Stockholm | Sweden |
Southwest Wales Cancer Institute, Swansea | UK |
The European Organization for the Research and Treatment of Cancer (EORTC), Brussels | International |
University of Glasgow, Glasgow | UK |
Vienna General Hospital | Austria |
Chilean Cooperative Group for Oncologic Research (GOCCHI) | Chile |
The Bank of Cyprus Oncology Centre, Nicosia | Cyprus |
Dept of Oncology of the 1st Faculty of Medicine Charles University and General Teaching Hospital, Prague | Czech Republic |
Rigshopitalet, Copenhagen | Denmark |
Institut Gustave Roussy, Villejuif | France |
West German Study Group / Frauenklinik der Heinrich-Heine- Universitaet Duesseldorf | Germany |
Universitaetsfrauenklinik – Frankfurt | Germany |
Dept. of OB/GYN, Technical University of Munich | Germany |
Universitaetsklinikum Eppendorf Hamburg | Germany |
National and Kapodistrian University of Athens | Greece |
St Vincent’s Hospital, Dublin | Ireland |
Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | Italy |
Centre Hospitalier de Luxembourg | Luxembourg |
University Maastricht / GROW | Netherlands |
Dept of Oncology & Radiotherapy, Medical University of Gdansk, Gdansk | Poland |
Portuguese Institute of Oncology, Porto Centre, Porto | Portugal |
N. N. Blokhin Cancer Research Centre, Moscow | Russia |
Institute of Oncology Ljubljana | Slovenia |
Institute of Oncology of Southern Switzerland | Switzerland |
Marmara University Hospital, Istanbul | Turkey |
Federation of European Cancer Societies | International |
Europa Donna | International |
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP) | Portugal |
International Institute for Drug Development | Belgium |
GSF – Research Centre for Environment and Health | Germany |
Agendia | Netherlands |
Vall d’Hebron University Hospital | Spain |
Grupo Espanol de Estudio y Tratamiento deTumores Solidos | Spain |
Swiss Institute of Bioinformatics | Switzerland |
The Chancellor, Masters and Scholars of the University of Oxford | United Kingdom |
Start date: 01/03/04
End date: 28/02/11
The TRANSBIG project received funding from the European Union’s European Commission’s Framework Programme VI under grant agreement number 503426.
ULTIMATE BIG 16-01 Share This Post An open-label, multicentre, international phase II trial testing durvalumab combined with endocrine therapy in patients with ER+/HER2- breast cancer
AMEERA-6 BIG 20-01 Share This Post A randomized, multicentre, double-blind, phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone
Breast international group (BIG) – aisbl
Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213
The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF
© 2022 All rights reserved
Breast international group (BIG) - aisbl